Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose monohydrate; magnesium stearate; crospovidone - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; hyprolose - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; hyprolose; magnesium stearate - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: hyprolose; crospovidone; lactose monohydrate; magnesium stearate - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose monohydrate; magnesium stearate; crospovidone - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Israel - English - Ministry of Health

abic marketing ltd, israel - olanzapine - film coated tablets - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine teva® is indicated for the management of the manifestations of psychotic disorders. olanzapine teva® is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment olanzapine teva® is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder. the combination of olanzapine teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - English - Ministry of Health

abic marketing ltd, israel - olanzapine - film coated tablets - olanzapine 10 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine teva is indicated for the management of the manifestations of psychotic disorders. olanzapine teva is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment olanzapine teva is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: pectin; mannitol; isopropyl alcohol; hyprolose; purified talc; lactose monohydrate; purified water; triacetin; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: purified water; lactose monohydrate; titanium dioxide; isopropyl alcohol; pectin; magnesium stearate; triacetin; hyprolose; purified talc; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; triacetin; isopropyl alcohol; pectin; titanium dioxide; magnesium stearate; hyprolose; mannitol; purified talc; purified water; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.